Skip to main content
. 2022 Jul;23(7):2431–2439. doi: 10.31557/APJCP.2022.23.7.2431

Table 3.

Association of CD44V6 and RCAS1 Expression with Clinicopathologic Variables of 52 Patients with Cervical Cancer

Clinicopathologic variables Total CD44v6 P value RCAS1 P value
Positive (%) Negative (%) Positive (%) Negative (%)
Histologic type <0.001* 0.001*
SCC 28 24 (80) 4 (18) 11 (35) 17 (81)
Adenocarcinoma 24 6 (20) 18 (82) 20 (65) 4 (19)
Age (years) 0.7 0.5
<45 23 14 (47) 9 (41) 15 (48) 8 (38)
≥45 29 16 (53) 13 (59) 16 (52) 13 (62)
Histologic grade <0.001* 0.057
G1 20 4 (13) 16 (73) 16 (52) 4 (19)
G2 16 16 (53) 0 (0) 7 (23) 9 (43)
G3 16 10 (33) 6 (27) 8 (26) 8 (38)
FIGO stage 0.3 0.3
I 48 29 (97) 19 (86) 30 (97) 18 (86)
II 4 1 (3.3) 3 (14) 1 (3.2) 3 (14)
Tumor size (mm) 0.030* 0.9
<25 24 10 (33) 14 (64) 14 (45) 10 (48)
≥25 28 20 (67) 8 (36) 17 (55) 11 (52)
LVSI 0.13 0.6
Negative 22 10 (33) 12 (55) 14 (45) 8 (38)
Positive 30 20 (67) 10 (45) 17 (55) 13 (62)
Pelvic lymph node metastasis 0.4 0.9
Negative 43 24 (83) 19 (95) 25 (89) 18 (86)
Positive 6 5 (17) 1 (5) 3 (11) 3 (14)
None 3 1 2 3 0
Recurrence 0.144 0.708
Negative 43 27 (90) 16 (73) 28 (85) 15 (79)
Positive 9 3 (10) 6 (27) 5 (15) 4 (21)

LVSI, Lymph-vascular space invasion; *P<0.05